Thus, a better understanding of the mechanisms by which tumor-associated myeloid cells activate FAK and PYK2 signaling and how these pathways contribute to T-ALL progression could reveal other therapeutic opportunities in T-ALL. The gene discussed is PTK2B; the disease is neoplasm.